Velimogene aliplasmid
- 2 April 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 10 (5) , 841-851
- https://doi.org/10.1517/14712598.2010.481280
Abstract
(2010). Velimogene aliplasmid. Expert Opinion on Biological Therapy: Vol. 10, No. 5, pp. 841-851. doi: 10.1517/14712598.2010.481280Keywords
This publication has 48 references indexed in Scilit:
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic MelanomaJournal of Clinical Oncology, 2009
- Recombinant Human Granulocyte-macrophage Colony-stimulating Factor (GM-CSF, Sargramostim) Administered for 3 Years as Adjuvant Therapy of Stages II(T4), III, and IV MelanomaJournal of Immunotherapy, 2009
- Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2008
- Cancer vaccines: on the threshold of successEmerging Drugs, 2008
- Allovectin-7 therapy in metastatic melanomaExpert Opinion on Biological Therapy, 2008
- Breaking Immune Suppression in Cancer: The Emerging Revolution in ImmunotherapyCancer Reviews Online Content, 2007
- Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic reviewCancer Treatment Reviews, 2007
- Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanomaBritish Journal of Dermatology, 2007
- Phase 2 trial of Allovectin-7 in advanced metastatic melanomaMelanoma Research, 2006
- Cancer Gene Therapy Using Plasmid DNA: Safety Evaluation in Rodents and Non-Human PrimatesHuman Gene Therapy, 1995